GalNAc-L96：高效RNA靶向递送的关键分子 ...

作为RNA靶向递送的核心配体，GalNAc-L96在siRNA和ASO疗法中发挥着关键作用。凭借领先的合成技术、严格的质量控制以及强大的定制化能力，沃尔森在该领域具有显著的竞争优势，助力RNA递送技术的突破与发展。 返回搜狐，查看更多 ...

Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort Multi-dosing ongoing in 200 mg cohort of RestorAATion-2 ...

Reports Q4 revenue $83.748M vs $29.056M. “2024 was an exceptional year for Wave and we’ve continued the positive momentum into 2025, with the ...

Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first ...

为解决肝癌治疗难题，复旦大学附属肿瘤医院的研究人员开展 FAM99B 相关研究。发现 FAM99B 可抑制核糖体生成和肝癌进展，GalNAc - FAM99B65 - 146 有治疗潜力。该研究为肝癌治疗提供新思路，值得科研人员阅读。 复旦大学附属肿瘤医院（Fudan University Shanghai Cancer Center ...